Today's Trend
Apellis Pharmaceuticals, Inc. (APLS) — Shares are reacting to a wave of analyst rating changes today after a recent run-up in the stock (twelve‑month high ~ $40.48). Trading volume is above average, suggesting investors are digesting the new analyst views. Recent fundamentals include an EPS beat on Feb. 24 and revenue roughly in line with expectations, but several sell‑side firms have trimmed recommendations after the recent rally.
- Mizuho raised its price target sharply from $20 to $41 (maintaining a neutral rating), implying modest upside from current levels and signaling greater confidence in valuation after the run-up. Mizuho raises PT
- Citigroup reaffirmed a neutral stance on Apellis (reporting coverage note). This keeps some institutional support for a non‑committal view despite other downgrades. Citigroup reaffirm
- JPMorgan is reporting a “neutral” rating in recent coverage notes — another signal that large banks are shifting to more cautious, hold/neutral stances instead of bullish calls. JPMorgan neutral
- Multiple major sell‑side firms downgraded Apellis (many moving from strong‑buy/overweight to hold/neutral): Roth MKM, Cantor Fitzgerald, Jefferies, William Blair, Robert W. Baird, HC Wainwright, Raymond James, Needham and others. These coordinated rating cuts are the primary near‑term driver putting downward pressure on the stock as investors lock in gains after the rally. Representative coverage: Zacks analyst downgrades roundup Cantor Fitzgerald downgrade Raymond James lowered
Bottom line for investors: momentum from strong upside over the past year has drawn reassessments from many analysts; the net effect today is increased selling pressure and higher volume as the market prices in a more cautious analyst consensus, even though a few firms (and the company’s recent beat) provide counterpoints. Monitor follow‑up notes from major brokers for any changes to price targets or near‑term guidance before repositioning.